Cover Image
市場調查報告書

敗血症:開發中產品分析

Sepsis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 213120
出版日期 內容資訊 英文 278 Pages
訂單完成後即時交付
價格
Back to Top
敗血症:開發中產品分析 Sepsis - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 278 Pages
簡介

所謂敗血症是細菌和其他的微生物入侵時,人體作出強烈反應的疾病。主要的症狀包含了發冷和顫抖,呼吸困難,血小板數減少,心跳功能異常,腹痛等。主要的易罹病素質有年齡和免疫疾病系的弱化等。主要的治療藥為抗生素和升壓藥等。

本報告提供全球各國治療敗血症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。 當ярみЬザゾ、世界各國ザソ敗血症治療用ソеユкьユ⑦製品ソ開發狀況ズコゆサ分析ウ、製品開發・上市ソ最新動向ビ、治驗ソ各段階ズやペ製品ソ一覽、主要企業ソк①иャユю、主ス藥劑ソ概要、最新ソ業界動向スジソ情報メれ屆んウネエ。

本報告提供全球各國治療敗血症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

敗血症概要

治療藥的開發

  • 敗血症開發中產品:概要
  • 敗血症開發中產品:比較分析

各企業開發中的敗血症治療藥

大學/研究機關研究中的敗血症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

敗血症治療藥:開發中的產品一覽(各企業)

敗血症治療藥:研究中的產品一覽(大學/研究機關)

敗血症治療藥的開發企業

  • Adrenomed AG
  • Altor BioScience Corporation
  • Am-Pharma B.V.
  • Arch Biopartners, Inc.
  • Aridis Pharmaceuticals LLC
  • 旭化成製藥
  • Astellas Pharma Inc.
  • Batu Biologics, Inc.
  • Biomedica Management Corporation
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cell2B S.A.
  • Chiesi Farmaceutici SpA
  • Chiome Bioscience, Inc.
  • Cilian AG
  • Cognosci, Inc.
  • Cytheris SA
  • Endacea, Inc.
  • Evec, Inc.
  • Huons Co., Ltd.
  • Immune Response BioPharma, Inc.
  • Immunethep, SA
  • ImmunNovative Developments SL
  • InflaRx GmbH
  • Inotrem S.A.
  • Integrated BioTherapeutics, Inc.
  • Lead Discovery Center GmbH
  • Merck & Co., Inc.
  • Navigen Pharmaceuticals, Inc.
  • OncoImmune, Inc.
  • Opsona Therapeutics Limited
  • Orion Oyj
  • ProThera Biologics, LLC.
  • Ra Pharmaceuticals, Inc.
  • Recce Pty Ltd
  • Ribomic Inc.
  • 鹽野義製藥
  • Silence Therapeutics Plc
  • SK Biopharmaceuticals Co., Ltd.
  • Stemedica Cell Technologies, Inc.
  • Syntiron LLC
  • TaiRx, Inc.
  • 武田藥品工業
  • Therakind Limited
  • Therashock, LLC
  • TiGenix NV
  • VBS Pharmaceuticals
  • ViiV Healthcare Limited
  • XImmune AB

敗血症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

敗血症治療藥:開發暫停的產品

敗血症治療藥:開發中止的產品

敗血症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿
  • ■附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8985IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2017, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sepsis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 10, 6, 1, 60, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 17 and 7 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 6
  • List of Figures 8
  • Introduction 9
  • Global Markets Direct Report Coverage 9
  • Sepsis - Overview 10
  • Sepsis - Therapeutics Development 11
  • Pipeline Overview 11
  • Pipeline by Companies 12
  • Pipeline by Universities/Institutes 17
  • Products under Development by Companies 20
  • Products under Development by Universities/Institutes 25
  • Sepsis - Therapeutics Assessment 28
  • Assessment by Target 28
  • Assessment by Mechanism of Action 31
  • Assessment by Route of Administration 34
  • Assessment by Molecule Type 36
  • Sepsis - Companies Involved in Therapeutics Development 38
  • Adrenomed AG 38
  • Altor BioScience Corp 38
  • Am-Pharma BV 39
  • Arch Biopartners Inc. 39
  • Aridis Pharmaceuticals LLC 40
  • Asahi Kasei Pharma Corp 40
  • Astellas Pharma Inc 41
  • Batu Biologics Inc 41
  • Biomedica Management Corp 42
  • Boehringer Ingelheim GmbH 42
  • Bristol-Myers Squibb Company 43
  • Cell2B Advanced Therapeutics SA 43
  • Chiome Bioscience Inc 44
  • Cilian AG 44
  • Dr. Franz Kohler Chemie GmbH 45
  • Endacea Inc 45
  • Evec Inc 46
  • Ferring International Center SA 46
  • Huons Co Ltd 47
  • Immune Response BioPharma Inc 47
  • Immunethep SA 48
  • InflaRx GmbH 48
  • Inotrem SA 49
  • Integrated BioTherapeutics Inc 49
  • Lead Discovery Center GmbH 50
  • Leading BioSciences Inc 50
  • Lixte Biotechnology Holdings Inc 51
  • Merck & Co Inc 51
  • Navigen Pharmaceuticals Inc 52
  • Nohla Therapeutics Inc 52
  • Novartis AG 53
  • OncoImmune Inc 53
  • Ono Pharmaceutical Co Ltd 54
  • Opsona Therapeutics Ltd 54
  • Peptinov SAS 55
  • ProThera Biologics Inc 55
  • Ra Pharmaceuticals Inc 56
  • Recce Ltd 56
  • Revimmune LLC 57
  • Ribomic Inc 57
  • SciClone Pharmaceuticals Inc 58
  • SetLance srl 58
  • Shionogi & Co Ltd 59
  • Silence Therapeutics Plc 59
  • SK Biopharmaceuticals Co Ltd 60
  • Spider Biotech 60
  • Stemedica Cell Technologies Inc 61
  • Syntiron LLC 61
  • TaiRx Inc 62
  • Takeda Pharmaceutical Company Ltd 62
  • Therakind Ltd 63
  • Therashock LLC 63
  • TiGenix NV 64
  • VBS Pharmaceuticals 64
  • Sepsis - Drug Profiles 65
  • (Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile 65
  • 3K3A-APC - Drug Profile 66
  • 7-H9 - Drug Profile 68
  • AB-012 - Drug Profile 69
  • AB-022 - Drug Profile 70
  • AcPepA - Drug Profile 71
  • adrecizumab - Drug Profile 72
  • ALT-836 - Drug Profile 73
  • AM-12 - Drug Profile 75
  • AM/AMBP-1 - Drug Profile 76
  • Aspidasept - Drug Profile 77
  • Atu-111 - Drug Profile 78
  • AyuV-25 - Drug Profile 79
  • BC-1215 - Drug Profile 80
  • BI-113823 - Drug Profile 81
  • Biologic to Inhibit PD-L1 for Immunology - Drug Profile 82
  • BMS-936559 - Drug Profile 83
  • BMS-986189 - Drug Profile 86
  • BRL-44408 - Drug Profile 87
  • C-23 - Drug Profile 88
  • CAR Peptide - Drug Profile 89
  • cefiderocol - Drug Profile 90
  • ceftaroline fosamil - Drug Profile 92
  • Cell Therapy for Sepsis - Drug Profile 95
  • Cx-611 - Drug Profile 96
  • CYT-107 - Drug Profile 100
  • Drug for Sepsis and Septic Shock - Drug Profile 103
  • Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 104
  • EC-18 - Drug Profile 105
  • Escherichia coli vaccine - Drug Profile 107
  • ethinylestradiol - Drug Profile 108
  • EV-007156 - Drug Profile 109
  • Gamma-PN - Drug Profile 110
  • Glyco-23 - Drug Profile 111
  • HBN-1 - Drug Profile 112
  • HBN-3 - Drug Profile 113
  • HBN-4 - Drug Profile 114
  • HU-003 - Drug Profile 115
  • IFX-1 - Drug Profile 116
  • ImmStem - Drug Profile 118
  • ImmuneSafe - Drug Profile 119
  • IMT-504 - Drug Profile 120
  • IR-999 - Drug Profile 122
  • Klebsiella pneumoniae vaccine - Drug Profile 123
  • L-257 - Drug Profile 124
  • L-971 - Drug Profile 125
  • LB-100 - Drug Profile 127
  • lodelcizumab - Drug Profile 130
  • M-33 - Drug Profile 131
  • M-6229 - Drug Profile 133
  • melatonin - Drug Profile 134
  • Metablok - Drug Profile 135
  • Monoclonal Antibodies for Sepsis - Drug Profile 136
  • Monoclonal Antibodies to Inhibit uPA for Acute Lung Injury,Acute Respiratory Distress Syndrome and Sepsis - Drug Profile 137
  • Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 138
  • Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 139
  • Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 140
  • Monoclonal Antibody to Inhibit iNOS for Sepsis - Drug Profile 141
  • Monoclonal Antibody to Inhibit Semaphorin 3A for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile 142
  • Motrem - Drug Profile 143
  • MSP-68 - Drug Profile 144
  • NAV-838 - Drug Profile 145
  • nivolumab - Drug Profile 146
  • NOXD-21 - Drug Profile 185
  • OPN-305 - Drug Profile 186
  • OTP-300 - Drug Profile 189
  • OTP-602 - Drug Profile 190
  • Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile 191
  • physostigmine salicylate - Drug Profile 192
  • pneumococcal vaccine - Drug Profile 193
  • PNV-1 - Drug Profile 194
  • Protein to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 195
  • Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 196
  • R-190 - Drug Profile 198
  • RA-101295 - Drug Profile 200
  • RBM-005 - Drug Profile 201
  • RECCE-327 - Drug Profile 202
  • Recombinant Alkaline Phosphatase Replacement for Sepsis - Drug Profile 204
  • Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile 205
  • Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 209
  • Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 210
  • Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 211
  • Recombinant Protein for Inflammation and Bacterial Sepsis - Drug Profile 212
  • Recombinant Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile 213
  • Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile 214
  • Recombinant Protein to Target Von Willebrand Factor Type A1 Domain for Sepsis - Drug Profile 215
  • SAN-101 - Drug Profile 216
  • SB-056 - Drug Profile 217
  • selepressin - Drug Profile 218
  • Slit-2N - Drug Profile 219
  • Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 221
  • Small Molecule to HDAC6 for Sepsis - Drug Profile 222
  • Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 223
  • Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 224
  • Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 225
  • Small Molecules to Inhibit DHFR for Septicaemia - Drug Profile 226
  • Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 227
  • Small Molecules to Inhibit Sialidase for Bacterial Sepsis - Drug Profile 228
  • SP-14 - Drug Profile 229
  • SP-9 - Drug Profile 230
  • Staphylococcus aureus (multivalent) vaccine - Drug Profile 231
  • Stem Cell Therapy for Autoimmune Diseases - Drug Profile 232
  • Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 234
  • Synthetic Peptide to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis and Hemorrhagic Shock - Drug Profile 240
  • Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 241
  • Synthetic Peptides for Infectious Disease - Drug Profile 242
  • Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis - Drug Profile 243
  • Synthetic Peptides for Oncology, Sepsis and Atherosclerosis - Drug Profile 244
  • TF-0003 - Drug Profile 245
  • thrombomodulin alfa - Drug Profile 246
  • thymalfasin - Drug Profile 248
  • tosatoxumab - Drug Profile 249
  • tranexamic acid - Drug Profile 251
  • TRX-306 - Drug Profile 253
  • vancomycin hydrochloride - Drug Profile 254
  • Yersinia pestis vaccine - Drug Profile 255
  • Sepsis - Dormant Projects 256
  • Sepsis - Discontinued Products 260
  • Sepsis - Product Development Milestones 262
  • Featured News & Press Releases 262
  • Appendix 269
  • Methodology 269
  • Coverage 269
  • Secondary Research 269
  • Primary Research 269
  • Expert Panel Validation 269
  • Contact Us 269
  • Disclaimer 270

List of Tables

  • Number of Products under Development for Sepsis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Sepsis - Pipeline by Adrenomed AG, H1 2017
  • Sepsis - Pipeline by Altor BioScience Corp, H1 2017
  • Sepsis - Pipeline by Am-Pharma BV, H1 2017
  • Sepsis - Pipeline by Arch Biopartners Inc., H1 2017
  • Sepsis - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
  • Sepsis - Pipeline by Asahi Kasei Pharma Corp, H1 2017
  • Sepsis - Pipeline by Astellas Pharma Inc, H1 2017
  • Sepsis - Pipeline by Batu Biologics Inc, H1 2017
  • Sepsis - Pipeline by Biomedica Management Corp, H1 2017
  • Sepsis - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Sepsis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017
  • Sepsis - Pipeline by Chiome Bioscience Inc, H1 2017
  • Sepsis - Pipeline by Cilian AG, H1 2017
  • Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H1 2017
  • Sepsis - Pipeline by Endacea Inc, H1 2017
  • Sepsis - Pipeline by Evec Inc, H1 2017
  • Sepsis - Pipeline by Ferring International Center SA, H1 2017
  • Sepsis - Pipeline by Huons Co Ltd, H1 2017
  • Sepsis - Pipeline by Immune Response BioPharma Inc, H1 2017
  • Sepsis - Pipeline by Immunethep SA, H1 2017
  • Sepsis - Pipeline by InflaRx GmbH, H1 2017
  • Sepsis - Pipeline by Inotrem SA, H1 2017
  • Sepsis - Pipeline by Integrated BioTherapeutics Inc, H1 2017
  • Sepsis - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Sepsis - Pipeline by Leading BioSciences Inc, H1 2017
  • Sepsis - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
  • Sepsis - Pipeline by Merck & Co Inc, H1 2017
  • Sepsis - Pipeline by Navigen Pharmaceuticals Inc, H1 2017
  • Sepsis - Pipeline by Nohla Therapeutics Inc, H1 2017
  • Sepsis - Pipeline by Novartis AG, H1 2017
  • Sepsis - Pipeline by OncoImmune Inc, H1 2017
  • Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Sepsis - Pipeline by Opsona Therapeutics Ltd, H1 2017
  • Sepsis - Pipeline by Peptinov SAS, H1 2017
  • Sepsis - Pipeline by ProThera Biologics Inc, H1 2017
  • Sepsis - Pipeline by Ra Pharmaceuticals Inc, H1 2017
  • Sepsis - Pipeline by Recce Ltd, H1 2017
  • Sepsis - Pipeline by Revimmune LLC, H1 2017
  • Sepsis - Pipeline by Ribomic Inc, H1 2017
  • Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H1 2017
  • Sepsis - Pipeline by SetLance srl, H1 2017
  • Sepsis - Pipeline by Shionogi & Co Ltd, H1 2017
  • Sepsis - Pipeline by Silence Therapeutics Plc, H1 2017
  • Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
  • Sepsis - Pipeline by Spider Biotech, H1 2017
  • Sepsis - Pipeline by Stemedica Cell Technologies Inc, H1 2017
  • Sepsis - Pipeline by Syntiron LLC, H1 2017
  • Sepsis - Pipeline by TaiRx Inc, H1 2017
  • Sepsis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Sepsis - Pipeline by Therakind Ltd, H1 2017
  • Sepsis - Pipeline by Therashock LLC, H1 2017
  • Sepsis - Pipeline by TiGenix NV, H1 2017
  • Sepsis - Pipeline by VBS Pharmaceuticals, H1 2017
  • Sepsis - Dormant Projects, H1 2017
  • Sepsis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Sepsis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Sepsis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Sepsis - Discontinued Products, H1 2017
  • Sepsis - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Sepsis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top